300119 瑞普生物
2024/06 - 中期
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
2020/12
人民币(K¥)
经营活动产生之现金流量净额195,839378,196389,487382,629388,439
投资活动产生之现金流量净额73,150(160,975)(1,244,732)(627,060)(243,070)
筹资活动产生之现金流量净额(211,957)(272,461)(48,346)1,260,320(169,858)
汇率变动对现金及现金等价物的影响3556444-0-0
现金及现金等价物净增加/(减少)57,387(55,175)(903,547)1,015,889(24,489)
期初现金及现金等价物余额321,530376,7051,280,252264,363288,852
期末现金及现金等价物余额378,917321,530376,7051,280,252264,363